Abstract Background/Aims: Hospitalizations account for 41% of the total cost of end-stage
renal disease (ESRD) care. Carnitine deficiency is common among dialysis patients, and …

Carnitine, gamma-trimethyl-beta-hydroxybutyrobetaine, is a small molecule widely present
in all cells from prokaryotic to eukaryotic. It is an important element in the beta-oxidation of …

There are many causes for carnitine depletion during maintenance hemodialysis.
Supplementation with L-carnitine in animals has been associated with improvement in some …

Carnitine has high dialyzability and is often deficient in dialysis patients. This deficiency is
treated by either intravenous (IV) or oral supplementation of carnitine. In this study, the mode …

Background L-carnitine levels decrease rapidly and steadily with duration of hemodialysis,
and carnitine depletion can impair response to recombinant human erythropoietin …

Carnitine is a conditionally essential metabolite that plays a critical role in cell physiology.
Carnitine is necessary for fatty acid transport to sites of beta-oxidation in the mitochondria …

It has been widely established that patients with end‐stage renal disease undergoing
chronic haemodialysis therapy exhibit low endogenous levels of L‐carnitine and elevated …

Careful review of all available clinical trials of L-carnitine leads to the conclusion that there is
insufficient evidence to support the routine use of L-carnitine for any indication in dialysis …

Abstract Carnitine, 3‐hydroxy‐4‐trimethylaminobutyrate, a small, water soluble molecule
that is essential for mitochondrial fatty acid oxidation, is significantly reduced in hemodialysis …

Exercise capacity in patients with end-stage renal disease (ESRD) remains impaired despite
correction ofanemia. Carnitine insufficiency may contribute to impaired exercise and …